Compare Crispr Therapeutics AG (CRSP) vs Dominion Energy Inc (D) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Dominion Energy Inc — how do they compare? Crispr Therapeutics AG trades at $50.76 (market cap $4.97B), while Dominion Energy Inc trades at $70.95 (market cap $62.71B). The key difference: Dominion Energy Inc is far larger — about 12.6× Crispr Therapeutics AG's market cap, and Dominion Energy Inc pays a 3.74% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | D | |
|---|---|---|
Market Cap | $4.97B | $62.71B |
Sector | Health | Utilities |
52-Week High | $76.78 | $71.32 |
52-Week Low | $44.34 | $56.55 |
Enterprise Value | $3.32B | $115.11B |
Dividend Yield | — | 3.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Dominion Energy (D) trades at $70.8, up 1.03% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $70.14. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.95, and maintains a solid net income margin of 16.93%. Recent news highlights a proposed $66.8 billion acquisition by NextEra Energy, positioning D at the center of AI-driven power demand trends.
The outlook for D is mixed; upside potential exists from rising electricity demand and strategic acquisitions, but risks include regulatory scrutiny of the NextEra deal and high debt levels. Analysts are cautious, with 59% holding a neutral rating, reflecting balanced opportunities and headwinds for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Dominion Energy Inc
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.
Read more on D →
